Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Caredx Inc is a diagnostics & research business based in the US. Caredx shares (CDNA) are listed on the NASDAQ and all prices are listed in US Dollars. Caredx employs 633 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $21.48 |
|---|---|
| 52-week range | $19.35 - $92.17 |
| 50-day moving average | $25.56 |
| 200-day moving average | $41.24 |
| Wall St. target price | $59.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.95 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $21.48 from 2022-06-30
| 1 week (2022-06-24) | -9.29% |
|---|---|
| 1 month (2022-06-02) | -18.82% |
| 3 months (2022-03-29) | -46.45% |
| 6 months (2021-12-31) | -52.77% |
| 1 year (2021-07-02) | -76.13% |
|---|---|
| 2 years (2020-07-02) | -38.04% |
| 3 years (2019-07-02) | 35.71 |
| 5 years (2017-06-30) | 1,835.14% |
| Revenue TTM | $308.4 million |
|---|---|
| Gross profit TTM | $199 million |
| Return on assets TTM | -5.4% |
| Return on equity TTM | -10.68% |
| Profit margin | -16.09% |
| Book value | $8.62 |
| Market capitalisation | $1.1 billion |
TTM: trailing 12 months
We're not expecting Caredx to pay a dividend over the next 12 months.
Over the last 12 months, Caredx's shares have ranged in value from as little as $19.345 up to $92.17. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Caredx's is 0.8126. This would suggest that Caredx's shares are less volatile than average (for this exchange).
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.